Abstract: By introducing at least one cysteine residue based on wild-type IL-2, the binding plane of the IL-2 derivative and ? receptor subunit is partially or completely blocked, while the affinity of the IL-2 derivative to the complex of ? and ? receptor subunits is basically retained. A complex includes an IL-2 derivative, which is introduced with a third cysteine residue based on wild-type IL-2; and a blocking module, which has or is introduced with a fourth cysteine residue. The third cysteine residue on the IL-2 derivative and the fourth cysteine residue on the blocking module are capable of forming an intermolecular disulfide bond, thereby forming a complex of the IL-2 derivative and the blocking module. The binding plane of the IL-2 derivative and ? receptor subunit is partially or completely blocked, while the affinity of the IL-2 derivative to the complex of ? and ? receptor subunits is basically retained.

Abstract: The amino acid sequence of the present IL-15 analog includes the amino acid sequence of IL-15 and an amino acid sequence including at least one positively charged amino acid added to the C-terminal of the amino acid sequence of IL-15. The present IL-15 analog is highly expressed in Escherichia Coli, wherein the expression level is about 20-fold higher than that of the wild-type IL-15, and there is no significant difference in cell activity in vitro. In addition, a conjugate of the IL-15 analog improves the half-life and the long-term efficacy of the IL-15 analog by coupling with the fatty acid chain. These improvements lay a foundation for the industrialization of IL-15 protein drugs.

Abstract: Novel analogues of Fibroblast Growth Factor 21 (FGF21), derivatives thereof having a modifying moiety covalently attached thereto, and pharmaceutical use of these analogues and derivatives, in particular, for the treatment of diabetes, dyslipidemia, obesity, cardiovascular diseases, metabolic syndrome, and/or Non Alcoholic Fatty Liver Disease (NAFLD) are described.

Abstract: Analogues of FGF21 carrying a modifying, substituted ethylene or benzyl group can be used for treatment or prevention of diabetes, dyslipidemia, obesity, cardiovascular diseases, metabolic syndrome, and/or Non Alcoholic Fatty Liver Disease (NAFLD).

Abstract: Derivatives of Fibroblast Growth Factor 21 which have improved properties for treating diabetes can be prepared by a recombinant process.

Abstract: The present invention relates to Fibroblast Growth Factor 21 (FGF21), more in particular to derivatives of FGF21 compounds having an albumin binder of the formula A-B-C-D-E- covalently attached. The invention also relates to novel FGF21 analogues, as well as to the pharmaceutical use of these FGF21 derivatives and analogues, in particular for the treatment of diabetes, dyslipidemia, obesity, cardiovascular diseases, metabolic syndrome, and/or Non Alcoholic Fatty Liver Disease (NAFLD). The derivatives of the invention are protracted, e.g. capable of maintaining a low blood glucose level for a longer period of time, capable of increasing the in vivo half-life of FGF21, and/or result in a lower clearance of FGF21. The derivatives of the invention are preferably furthermore of an improved oxidative stability.